Sun Pharmaceutical Industries Ltd.

Further to its intimation letter dated December 12, 2023, Sun Pharmaceutical Industries has informed that the company (together with its subsidiaries and/or affiliates referred to as ‘Sun Pharma’), have entered into a definitive merger agreement (‘Merger Agreement’) with Taro Pharmaceutical Industries (‘Taro’), pursuant to which Sun Pharma has agreed to acquire all of the outstanding ordinary shares of Taro not currently held by Sun Pharma. The transaction is subject to approvals of the shareholders of Taro, including the majority of its minority shareholders participating in the vote, and subject to other requisite statutory approvals as per the applicable laws. In this connection, it has enclosed the following; Annexure A containing particulars of the disclosure required as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Annexure B is a joint press release of Sun Pharma and Taro which will be released after filing this intimation.

The above information is a part of company’s filings submitted to BSE.